A Multicenter, Randomized, Double-Blind Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Gemcitabine and Nab-Paclitaxel Versus Placebo Combined With Gemcitabine and Nab-Paclitaxel in First Line Advanced Pancreatic Ductal Adenocarcinoma Subjects (ENREACH-PDAC-01).

Jiangsu Alphamab Biopharmaceuticals Co., Ltd65 sites in 1 country408 target enrollmentJanuary 20, 2022

ConditionsAdvanced Pancreatic Ductal Adenocarcinoma

InterventionsKN046 placebo

DrugsKN046 placebo

Overview

Phase: Phase 3
Intervention: KN046
Conditions: Advanced Pancreatic Ductal Adenocarcinoma
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Enrollment: 408
Locations: 65
Primary Endpoint: Overall Survival (OS)
Status: Active, not recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

Registry

clinicaltrials.gov

Start Date

January 20, 2022

End Date

August 30, 2024

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age ≥18, male or female;
•Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);
•Has not received prior systemic treatment for their locally advanced or metastatic PDAC;
•Has presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1);
•Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status;
•Has a life expectancy of at least 3 months;
•Has adequate organ function;
•If female of childbearing potential, have a negative serum pregnancy test within 7 days prior to first trial treatment;
•If female of childbearing potential or a male subject with a partner with childbearing potential, be willing to use a highly effective method of contraception (with a failure rate of less than 1.0% per year) from first study treatment to 24 weeks after completion of the trial treatment.

Exclusion Criteria

•Untreated active CNS metastasis or leptomeningeal metastasis.
•Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first dose of trial treatment;
•Has received other anti-tumor treatment within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first trial treatment;
•Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment and/or if the subject has not fully recovered from the surgery within 4 weeks of the first administration of trial treatment;
•Curative radiation within 3 months of the first dose of trial treatment. Radiation to more than 30% of the bone marrow or with a wide field of radiation should not be used within 4 weeks prior to the first administration of trial treatment;
•Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement doses, equivalent to \< 10 mg prednisone daily, inhaled steroids and topical use of steroids);
•Vaccination within 28 days of the first administration of trial treatment, except for administration of inactivated vaccines (e.g., inactivated influenza vaccines);
•Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;
•History or current active autoimmune disease that might deteriorate when receiving an immunostimulatory agent；
•Previous malignant disease History of uncontrolled intercurrent illness Prior therapy with any antibody/drug targeting T cell coregulatory proteins Known severe hypersensitivity reactions to antibody drug；

Arms & Interventions

Experimental arm

Intervention: KN046

Control arm

Intervention: placebo

Outcomes

Primary Outcomes

Overall Survival (OS)

Time Frame: up to 2 years

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up.